| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/29/2002 | EP1207878A2 Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof |
| 05/29/2002 | EP1207868A1 Pharmaceutical tramadol salts |
| 05/29/2002 | EP1207867A1 Oral pharmaceutical forms of administration with a delayed action |
| 05/29/2002 | EP1207866A1 Delayed-action form of administration containing tramadol saccharinate |
| 05/29/2002 | EP1207863A2 New uses for potassium channel openers, such as the treatment of epilepsy |
| 05/29/2002 | EP1207860A1 Controlled release pellet formulation |
| 05/29/2002 | EP1207858A1 Oral dosage forms |
| 05/29/2002 | EP1207856A2 Coformulation methods and their products |
| 05/29/2002 | EP1104419B1 N-substituted azabicycloheptane derivatives, production and use thereof |
| 05/29/2002 | EP0888325B1 Novel cyclic amino acids as pharmaceutical agents |
| 05/29/2002 | EP0857066B1 Use of nitroflavonoids for the treatment of anxiety |
| 05/29/2002 | EP0678021B1 Methods for the improvement of cognition with partial agonists of the glycine nmda receptor complex |
| 05/29/2002 | DE10059020A1 Parenteral applizierbare Darreichungsformen Dosage forms can be administered parenterally |
| 05/29/2002 | DE10045832A1 Verfahren zur Herstellung chiraler Verbindungen A process for preparing chiral compounds |
| 05/29/2002 | CN1351614A Human antibodies that bind human IL-12 and methods for producing |
| 05/29/2002 | CN1351609A Low-molecular inhibitors of complement proteases |
| 05/29/2002 | CN1351604A Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease |
| 05/29/2002 | CN1351602A New pharmaceutically active compounds |
| 05/29/2002 | CN1351599A Indole-type derivatives as inhibitors of P38 kinase |
| 05/29/2002 | CN1351592A Acyl derivatives which treat VL4-4 related disorders |
| 05/29/2002 | CN1351591A 抗炎吲哚衍生物 Indomethacin derivative |
| 05/29/2002 | CN1351496A Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk |
| 05/29/2002 | CN1351473A Composition |
| 05/29/2002 | CN1085687C Polymeric matrices and their uses in pharmaceutial compositions |
| 05/29/2002 | CN1085667C Substituted tetracylic azepine derivatives having affinity for 5-HT2 receptors |
| 05/29/2002 | CN1085659C 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
| 05/29/2002 | CN1085532C Medicine for giving up medicinal dependence |
| 05/29/2002 | CN1085531C Preparation for protecting liver and relieving acute alcoholism and its preparing method |
| 05/29/2002 | CN1085529C Use of [R-(Z)]-alpha-(methoxyimino)-alpha-[1-azabicyclw[2.2.2.]oct-3-yl] acetonitrile to reduce amyloid beta A4 formation in Alzheimers disease |
| 05/28/2002 | US6395960 A genetically engineered rodent; diagnosis and therapy for alzheimer's disease |
| 05/28/2002 | US6395909 Drugs for anticonvulsants |
| 05/28/2002 | US6395905 Tetrahydroindazole derivatives as ligands for GABA-A α 5 receptors |
| 05/28/2002 | US6395901 Multistage reaction with calcium borohydride, alkylsulfonyl chloride, alkali metal mercapto compound and reducing agent for preparation of compounds active in the treatment of parkinson's disease, |
| 05/28/2002 | US6395897 Drugs for enzyme inhibitors anticoagulants and treatment of autoimmune disease |
| 05/28/2002 | US6395788 Methods and compositions for treating or preventing sleep disturbances and associated illnesses using very low doses of cyclobenzaprine |
| 05/28/2002 | US6395786 Sleep inducing agent |
| 05/28/2002 | US6395784 Obesity, hypercholesterolemia, atherosclerosis, thyroid cancer, hypothyroidism, osteoporosis, depression, arrhythmia, and congestive heart failure treatment |
| 05/28/2002 | US6395783 Treatment of PCP addiction and PCP addiction-related behavior |
| 05/28/2002 | US6395780 Prevent glucose degradation |
| 05/28/2002 | US6395768 Preventing cytotoxic effect of amyloid protein; oxidation, stress resistance |
| 05/28/2002 | US6395767 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| 05/28/2002 | US6395766 Cognition activators |
| 05/28/2002 | US6395764 Nosal decongestion, respiratory system disorders |
| 05/28/2002 | US6395763 Antitumor, anticancer agents; immunosuppressant |
| 05/28/2002 | US6395758 Small molecule carbamates or ureas for vision and memory disorders |
| 05/28/2002 | US6395748 Use treating Alzheimer's disease; monoamine reuptake inhibitor tropanes such as tesofensine (2-methoxymethyl-3-(3,4-dichlorophenyl)-tropane) |
| 05/28/2002 | US6395735 An indane-like compounds which can be useful for treating psychosis and other conditions associated with modulation of a muscarinic receptor |
| 05/28/2002 | US6395729 Use of pyridazino[4,5-b]indole-1-acetamide derivatives for preparing medicines for treating diseases related to the dysfunction of peripheral benzodiazepin receptors |
| 05/28/2002 | US6395727 Method of treating Bulimia Nervosa and related eating disorders by administration of atypical antipsychotic medications |
| 05/28/2002 | US6395725 Prevention or reverse drug resistance |
| 05/28/2002 | US6395719 Methods for increasing levels of acetylcholine |
| 05/28/2002 | US6395513 Clostridial toxin derivatives able to modify peripheral sensory afferent functions |
| 05/28/2002 | US6395502 Method and means for modulating PGE synthase activity |
| 05/28/2002 | US6395476 Evaluating long term outcome of viral disease infection; obtain sample, obtain viral nucleotide sequence from sample, screen sequences for presence of mutation in preferential codon, presence of mutation indicate more sever viral disease |
| 05/28/2002 | US6395304 Apparatus and method for preparing microparticles |
| 05/28/2002 | US6395299 Matrices for drug delivery and methods for making and using the same |
| 05/28/2002 | US6395279 Mixture of at least two phytochemicals including isoflavones, lignins, saponins, catechins, and phenolic acids |
| 05/28/2002 | US6395277 Method and compositions for the treatment of cerebral palsy |
| 05/28/2002 | US6395266 Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| 05/28/2002 | CA2209513C Arachidonic acid and methods for the production and use thereof |
| 05/28/2002 | CA2192675C Methods for treating motor deficits |
| 05/28/2002 | CA2165433C Novel chemical compounds having pde-iv inhibition activity |
| 05/28/2002 | CA2118997C Benzimidazole derivatives, their preparation and use |
| 05/28/2002 | CA2064325C External preparation for application to the skin containing lidocaine |
| 05/23/2002 | WO2002041002A2 Discordant helix stabilization for prevention of amyloid formation |
| 05/23/2002 | WO2002040700A2 Corticotropin releasing factor receptor 2 deficient mice and uses thereof |
| 05/23/2002 | WO2002040671A2 Immunoglobulin superfamily proteins |
| 05/23/2002 | WO2002040666A2 Fat regulated genes, uses thereof, and compounds for modulating same |
| 05/23/2002 | WO2002040649A1 Slo2 and slo4, novel potassium channel proteins from human brain |
| 05/23/2002 | WO2002040531A1 Lapemis hardwicki short chain neurotoxin and gene encoding it |
| 05/23/2002 | WO2002040517A2 M. tuberculosis chaperonin 60.1 and uses thereof |
| 05/23/2002 | WO2002040508A2 Lactam dipeptide and its use in inhibiting beta-amyloid peptide release |
| 05/23/2002 | WO2002040506A2 Modified clostridial neurotoxins with altered biological persistence |
| 05/23/2002 | WO2002040498A2 Reduction of antioxidant enzyme levels in tumor cells using antisense oligonucleotides |
| 05/23/2002 | WO2002040487A2 Benzodiazepine derivatives as gaba a receptor modulators |
| 05/23/2002 | WO2002040486A2 METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS |
| 05/23/2002 | WO2002040480A2 Crf receptor antagonists and methods relating thereto |
| 05/23/2002 | WO2002040476A1 Pyridyl-substituted triazoles as tgf inhibitors |
| 05/23/2002 | WO2002040475A1 Bombesin receptor antagonists |
| 05/23/2002 | WO2002040471A2 Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| 05/23/2002 | WO2002040469A1 Bombesin receptor antagonists |
| 05/23/2002 | WO2002040468A1 Compounds |
| 05/23/2002 | WO2002040466A2 Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives for treating of nervous systems disorders |
| 05/23/2002 | WO2002040462A2 Cysteine protease inhibitors |
| 05/23/2002 | WO2002040457A1 Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor |
| 05/23/2002 | WO2002040456A1 Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor |
| 05/23/2002 | WO2002040453A1 Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists |
| 05/23/2002 | WO2002040451A2 Lactam compound |
| 05/23/2002 | WO2002040450A1 (dihydro)isoquinoline derivatives as phosphodiesterase inhibitors |
| 05/23/2002 | WO2002040038A2 M. tuberculosis chaperonin 10 and uses thereof |
| 05/23/2002 | WO2002040037A2 M. tuberculosis chaperonin 60.1 and uses thereof |
| 05/23/2002 | WO2002040032A2 Cytoprotective estrogen derivatives |
| 05/23/2002 | WO2002040027A1 Treatment of premature ejaculation |
| 05/23/2002 | WO2002040024A1 Novel uses of combined 5-ht1a agonists and serotonin reuptake inhibitors |
| 05/23/2002 | WO2002040019A1 Benzimidazole derivatives |
| 05/23/2002 | WO2002040016A2 Association of calpain inhibitors and reactive oxygen species trapping agents |
| 05/23/2002 | WO2002040015A1 Protein prenyl transferase inhibitors in the treatment of neuroinflammatory disease |
| 05/23/2002 | WO2002040009A1 Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity |
| 05/23/2002 | WO2002040006A2 Treatment of anxiety disorders |
| 05/23/2002 | WO2002040005A2 Blockade of sodium channels by phenol derivatives |